10583710

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1626GMS

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	JUN 06	EPFULL enhanced with 260,000 English abstracts
NEWS 3	JUN 06	KOREAPAT updated with 41,000 documents
NEWS 4	JUN 13	USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications
NEWS 5	JUN 19	CAS REGISTRY includes selected substances from web-based collections
NEWS 6	JUN 25	CA/CAplus and USPAT databases updated with IPC reclassification data
NEWS 7	JUN 30	AEROSPACE enhanced with more than 1 million U.S. patent records
NEWS 8	JUN 30	EMBASE, EMBAL, and LEMBASE updated with additional options to display authors and affiliated organizations
NEWS 9	JUN 30	STN on the Web enhanced with new STN AnaVist Assistant and BLAST plug-in
NEWS 10	JUN 30	STN AnaVist enhanced with database content from EPFULL
NEWS 11	JUL 28	CA/CAplus patent coverage enhanced
NEWS 12	JUL 28	EPFULL enhanced with additional legal status information from the epoline Register
NEWS 13	JUL 28	IFICDB, IFIPAT, and IFIUDB reloaded with enhancements
NEWS 14	JUL 28	STN Viewer performance improved
NEWS 15	AUG 01	INPADOCDB and INPAFAMDB coverage enhanced
NEWS 16	AUG 13	CA/CAplus enhanced with printed Chemical Abstracts page images from 1967-1998
NEWS 17	AUG 15	CAOLD to be discontinued on December 31, 2008
NEWS 18	AUG 15	CAplus currency for Korean patents enhanced
NEWS 19	AUG 27	CAS definition of basic patents expanded to ensure comprehensive access to substance and sequence information
NEWS 20	SEP 18	Support for STN Express, Versions 6.01 and earlier, to be discontinued
NEWS 21	SEP 25	CA/CAplus current-awareness alert options enhanced to accommodate supplemental CAS indexing of exemplified prophetic substances
NEWS 22	SEP 26	WPIDS, WPINDEX, and WPIX coverage of Chinese and and Korean patents enhanced
NEWS 23	SEP 29	IFICLS enhanced with new super search field
NEWS 24	SEP 29	EMBASE and EMBAL enhanced with new search and display fields
NEWS 25	SEP 30	CAS patent coverage enhanced to include exemplified

prophetic substances identified in new Japanese-language patents
NEWS 26 OCT 07 EPFULL enhanced with full implementation of EPC2000
NEWS 27 OCT 07 Multiple databases enhanced for more flexible patent number searching

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 13:02:16 ON 16 OCT 2008

=>
Uploading
THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE
Do you want to switch to the Registry File?
Choice (Y/n):
Switching to the Registry File...
Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> FILE REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 13:02:30 ON 16 OCT 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 15 OCT 2008 HIGHEST RN 1061881-29-5
DICTIONARY FILE UPDATES: 15 OCT 2008 HIGHEST RN 1061881-29-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10583710.str





chain nodes :
13 14 20 22
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 15 16 17 18 19
chain bonds :
5-13 8-14 13-14 14-20 14-22 15-20
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 15-16 15-19
16-17 17-18 18-19
exact/norm bonds :
5-13 8-14 13-14 14-20 14-22 15-16 15-19 15-20 16-17 17-18 18-19
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12
isolated ring systems :

containing 1 : 7 : 15 :

G1:O,S

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:CLASS 14:CLASS 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:CLASS 22:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 O,S

Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 13:02:50 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 48 TO ITERATE

100.0% PROCESSED 48 ITERATIONS 10 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 545 TO 1375
PROJECTED ANSWERS: 11 TO 389

```
L2           10 SEA SSS SAM L1

=> s l1 sss full
FULL SEARCH INITIATED 13:02:57 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -     1097 TO ITERATE

100.0% PROCESSED     1097 ITERATIONS                              243 ANSWERS
SEARCH TIME: 00.00.01

L3          243 SEA SSS FUL L1

=> FIL HCAPLUS
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                     178.36     178.57

FILE 'HCAPLUS' ENTERED AT 13:03:08 ON 16 OCT 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 16 Oct 2008  VOL 149 ISS 16
FILE LAST UPDATED: 15 Oct 2008  (20081015/ED)

HCAplus now includes complete International Patent Classification (IPC)
reclassification data for the second quarter of 2008.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=> s l3
L4           9 L3

=> s l4 and py<=2003
      24009803 PY<=2003
L5           3 L4 AND PY<=2003

=> d l5 ibib abs hitstr tot

L5   ANSWER 1 OF 3  HCAPLUS  COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:        1981:443104  HCAPLUS
DOCUMENT NUMBER:         95:43104
ORIGINAL REFERENCE NO.:  95:7381a
```

TITLE: Bicyclic thiadiaza compounds and their use as medicaments
INVENTOR(S): Goeschke, Richard; Ferrini, Pier Giorgio
PATENT ASSIGNEE(S): Ciba-Geigy A.-G., Switz.
SOURCE: Brit. UK Pat. Appl., 11 pp.
CODEN: BAXXDU
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 2039882	A	19800820	GB 1979-427	19790105 <--
PRIORITY APPLN. INFO.:			GB 1979-427 A	19790105

OTHER SOURCE(S): MARPAT 95:43104
GI



I

AB The preparation of the title compds. I (R, R1 = optionally substituted Ph, pyridyl, thienyl; X = C2-4 alkylene; n = 0, 1, 2) is described. Thus, 5,6-bis(p-methoxyphenyl)imidazolo[2,1-b]dihydrothiazole (II) was prepared from 4,5-bis(p-methoxyphenyl)-2-mercaptoimidazole by treatment with 1.5% NaOH-Br(CH2)2Br-NaCO3-Me2CHOH (6 h, reflux) followed by treatment with 20% KOH. I have antiinflammatory, antirheumatic, analgesic, antithrombotic, and prostaglandin synthetase-inhibiting activity. They are useful in the treatment of rheumatoid arthritis. Compns. containing II are described.

IT 70827-22-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and cyclocondensation reaction of)

RN 70827-22-4 HCAPLUS

CN Benzeneethanol, 4-methoxy-α-(4-methoxyphenyl)-β-(2-thiazolylamino)- (CA INDEX NAME)



L5 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1979:457003 HCAPLUS
DOCUMENT NUMBER: 91:57003
ORIGINAL REFERENCE NO.: 91:9239a,9242a
TITLE: Bicyclic thiadiaza compounds
PATENT ASSIGNEE(S): Ciba-Geigy A.-G., Switz.
SOURCE: Jpn. Kokai Tokkyo Koho, 12 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 54016470	A	19790207	JP 1978-81533	19780706 <--
EP 353	A2	19790124	EP 1978-100272	19780629 <--
R: BE, CH, DE, FR, GB, NL, SE				
EP 19688	A1	19810210	EP 1980-101323	19780629 <--
R: BE, CH, DE, FR, GB, NL, SE				
FI 7802132	A	19790108	FI 1978-2132	19780703 <--
AU 7837788	A	19800110	AU 1978-37788	19780705 <--
DK 7803055	A	19790108	DK 1978-3055	19780706 <--
NO 7802357	A	19790109	NO 1978-2357	19780706 <--
ZA 7803898	A	19790725	ZA 1978-3898	19780706 <--
DD 138212	A5	19791017	DD 1978-206565	19780706 <--
AT 7804917	A	19800315	AT 1978-4917	19780706 <--
AT 359078	B	19801027		
DD 145538	A5	19801217	DD 1978-214990	19780706 <--
SU 873886	A3	19811015	SU 1978-2632647	19780706 <--
HU 29077	A2	19840130	HU 1981-3495	19780706 <--
PL 116596	B1	19810630	PL 1978-208253	19780707 <--
SU 893134	A3	19811223	SU 1979-2763599	19790518 <--
AT 7906667	A	19800615	AT 1979-6667	19791012 <--
AT 360526	B	19810112		
AT 7906668	A	19800615	AT 1979-6668	19791012 <--
AT 360527	B	19810112		
AT 7906669	A	19800615	AT 1979-6669	19791012 <--
AT 360528	B	19810112		
SU 850007	A3	19810723	SU 1979-2831085	19791023 <--
SU 873887	A3	19811015	SU 1979-2855458	19791220 <--
ES 487583	A5	19810116	ES 1980-487583	19800110 <--
EP 20858	A1	19810107	EP 1980-101322	19800313 <--
R: BE, CH, DE, FR, GB, NL, SE				

PRIORITY APPLN. INFO.:

LU 1977-77703	A	19770707
AT 1978-4917	A	19780706
US 1979-2565	A	19790111
US 1979-47084	A	19790611
JP 1979-103495	A	19790814

OTHER SOURCE(S): MARPAT 91:57003
GI



I



II



III

AB I and II (R, R1 = Ph, pyridyl, thienyl; X = alkylene; n = 0, 1, 2; m = 1, 2) were prepared, e.g. by cyclization of III. I and II were antiinflammatory agents (10 mg/kg). Thus, heating p-MeOC6H4COCHBrC6H4OMe-p with 2-aminothiazoline in EtOH 4 h at 60°, refluxing 2 h and stirring 12 h at room temperature gave II (R = R1 = p-MeOC6H4, m = 1).

IT 70827-22-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(cyclization of, imidazothiazole derivative from)

RN 70827-22-4 HCAPLUS

CN Benzeneethanol, 4-methoxy-α-(4-methoxyphenyl)-β-(2-thiazolylamino)- (CA INDEX NAME)



IT 70827-24-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with hydrogen bromide)

RN 70827-24-6 HCAPLUS

CN Ethanone, 1,2-bis(4-methoxyphenyl)-2-(2-thiazolylamino)- (CA INDEX NAME)



L5 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1954:826 HCAPLUS
DOCUMENT NUMBER: 48:826
ORIGINAL REFERENCE NO.: 48:141h-i,142a-d
TITLE: Tertiary amines derived from N-(2-pyridyl, 2-thiazolyl, and 2-lepidyl)-1,2-diphenylethylamine
AUTHOR(S): Kaye, Irving Allan; Parris, Chester L.
CORPORATE SOURCE: Brooklyn Coll., Brooklyn, NY
SOURCE: Journal of the American Chemical Society (1952), 74, 1566-8
CODEN: JACSAT; ISSN: 0002-7863
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable

AB cf. C.A. 47, 8746c. Some secondary amines could be alkylated in the presence of LiNH2 with alkyl halides and styrene oxide to yield products desired for testing as potential antimitotic agents, reaction between CH2PhCHPhCl (I) and either 2-aminopyridine (II) or N,N-dimethyl-N'-(2-pyridyl)ethylenediamine (III) under the same conditions yielded only trans-stilbene. Preliminary pharmacol. tests of the ability of the compds. prepared to retard the growth of sarcoma 180, or as antihistamine agents are reported. All m.ps. are corrected 2-Chlorolepidine (30.2 g.) and 67.1 g. CH2PhCH(Ph)NH2 (IV) let react until the temperature fell to 100°, 300 cc. C6H6 added, the mixture refluxed 12 hrs., IV.HCl filtered off (m. 256-8°), and the filtrate evaporated yielded 29.6 g. 2-(1,2-diphenylethyl)aminolepidine, m. 135-6°. IV (59.2 g.) yielded 68.6 g. 1,2-diphenylethyl isothiocyanate (V), b0.07 120-1°. V (62.2 g.) in 150 cc. each Me2CO and concentrated NH4OH yielded 63.7 g. N-(1,2-diphenylethyl)thiourea (VI), m. 171-1.5°. VI (28.2 g.), 15.0 g. ClCH2CH(OMe)2, and 100 cc. water heated 2.5 hrs. on the steam bath, dilute NaOH added, the gum extracted with Et2O and the Et2O evaporated yielded 2-(1,2-diphenylethyl)aminothiazole. 2-(1,2-Diphenylethylamino)pyridine (13.9 g.), 7.2 g. styrene oxide, 1.5 g. LiNH2, and 100 cc. C6H6 refluxed 24 hrs., the mixture shaken with 500 cc. water, and the C6H6 exts. evaporated, yielded 18.1 g. N-(1,2-diphenylethyl)-N-(2-pyridyl)-1-phenyl-2-aminoethanol, b0.03 200-2°. PhCH2CHPhOH (464.1 g.) in 950 cc. (CH2Cl)2 treated dropwise during 1 hr. with 350 g. SOCl2 (temperature held below 10°), the mixture let stand 18 hrs., and distilled in vacuo yielded 426.4 g. I, b5 146-9°. III (23.0 g.), 32.5 g. I, 3.9 g. LiNH2, and 150 cc. C6H6 yielded 20.2 g. trans-stilbene, m. 124-5°. The results were similar with II instead of III. For secondary and tertiary amines, PhCH2CH(Ph)NRR', R, R', b.p./mm., m.p., and yield are: 2-pyridyl

(VII), H, 157-9°/0.08, 65-6°, 73 (picrate, m. 185-6.5); 2-thiazolyl, H, 200-2°/0.60, 103.5-4.5°, 84; VII, CH2CH2NMe2, 161-3°/0.05, 168.5-9.5° (oxalate), 97; VII, CH2CH2NEt2, 174-7°/0.03, 129-9.5° (oxalate), 97; VII, (CH2)3NEt2, 179-83°/0.07, -, 97: VII 2-(1-pyrrolidylethyl), 181-3/0.05, 183-4 (oxalate, decomposition), 96; VII, 2-morpholinoethyl, 205-7°/0.11, 96.5-7.5° (oxalate 176.5-77°), 98; VII, CH2CH2N(CH2Ph)2, -, 114-15°, 94; VII, CH2CH2SMe, 184-5°/0.09, 74-5°, 95; VII, CHCH(OH)Ph, 200-2°/0.03, -, 92; 2-thiazolyl, CH2CH2NMe2, 173-6°/0.02, 142-3° (picrate), 82; 2-lepidyl, CH2CH2NMe2, 215-17°/0.04, 171-2° (picrate), 93.

IT 859474-57-0P, Thiazole, 2-(1,2-diphenylethylamino)- 859477-34-2P, Thiazole, 2-[(2-dimethylaminoethyl)(1,2-diphenylethyl)amino]- 859477-35-3P, Thiazole, 2-[(2-dimethylaminoethyl)(1,2-diphenylethyl)amino]-, picrate
RL: PREP (Preparation)
(preparation of)

RN 859474-57-0 HCAPLUS
CN 2-Thiazolamine, N-(1,2-diphenylethyl)- (CA INDEX NAME)



RN 859477-34-2 HCAPLUS
CN 1,2-Ethanediamine, N1-(1,2-diphenylethyl)-N2,N2-dimethyl-N1-2-thiazolyl- (CA INDEX NAME)



RN 859477-35-3 HCAPLUS
CN Thiazole, 2-[(2-dimethylaminoethyl)(1,2-diphenylethyl)amino]-, picrate (5CI) (CA INDEX NAME)

CM 1

CRN 859477-34-2
CMF C21 H25 N3 S



CM 2

CRN 88-89-1
CMF C6 H3 N3 O7



=> d l4 ibib abs hitstr tot

L4 ANSWER 1 OF 9 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2008:1157496 HCAPLUS
TITLE: Preparation of 4,5-dihydro-1,3-thiazol-2-amine derivatives and 4,5-dihydro-1H-imidazol-2-amine derivatives for use in treatment of respiratory, cardiovascular, neurological, and gastrointestinal disorders
INVENTOR(S): Bergman, Rolf; Calaza-Cabanas, Isabel; Johansson, Anders M.; Svensson-Henriksson, Anette Marie; Thorstensson, Fredrik
PATENT ASSIGNEE(S): Albireo AB, Swed.
SOURCE: PCT Int. Appl., 47pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008115141	A1	20080925	WO 2008-SE50300	20080318
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.:

US 2007-895521P	P	20070319
US 2007-895525P	P	20070319
US 2007-895532P	P	20070319

GI



I



IV



II



III

AB The present invention relates to compds. of formula I [Ar1 = (substituted) Ph group; Ar2 = IV; R = halogen, OH, C1-3 (fluorinated) alkyl;n = 0, 1-4; X, Y, Z = C, N; Ar1, Ar2 may attached to each other or together form fused ring], II (R1 = H, Ph, allyl; R2 = H, OH, C1-3 alkyl; m = 1, 2), and III (R3 = H, C1-5 alkyl; R4 = H, halogen, C1-3 alkyl, C1-3 alkoxy, OH, 4-carbamoyl, 4-methylcarbamoyl, 4-dimethylcarbamoyl; R5 = H, halogen, C1-3 alkyl, C1-3 alkoxy, OH; X' = O, S, NH), pharmaceutical compns. containing the compds., and the use of the compds. in the treatment of respiratory, cardiovascular, neurol., and gastrointestinal disorders. The present invention further relates to processes for the preparation of the above compds. and some intermediates used in the preparation thereof. Thus N-(1,2-diphenylethyl)-4,5-dihydro-1,3-thiazol-2-amine acetate was synthesized by the reaction of 1,2-diphenylethanamine and 2-chloroethyl isothiocyanate and was subjected to the potency test against active human α2A and α2B receptors. In general, the compds. of the invention demonstrated statistically significant agonistic activity at the α2A and/or α2B receptors at low levels.

IT 1058720-68-5P 1058720-70-9P 1058720-72-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of thiazolamine and imidazolamine derivs. for treatment of respiratory, cardiovascular, neurol., and gastrointestinal disorders)

RN 1058720-68-5 HCAPLUS

CN 2-Thiazolamine, N-(1,2-diphenylethyl)-4,5-dihydro-, acetate (1:1) (CA INDEX NAME)

CM 1

CRN 858862-85-8
CMF C17 H18 N2 S



CM 2

CRN 64-19-7
CMF C2 H4 O2



RN 1058720-70-9 HCAPLUS
CN Phenol, 4-[1-[(4,5-dihydro-2-thiazolyl)amino]-2-phenylethyl]-, acetate (1:1) (CA INDEX NAME)

CM 1

CRN 1058720-69-6
CMF C17 H18 N2 O S



CM 2

CRN 64-19-7
CMF C2 H4 O2



RN 1058720-72-1 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

CM 1

CRN 1058720-71-0
CMF C17 H18 N2 O2 S



CM 2

CRN 64-19-7
CMF C2 H4 O2



IT 1058720-71-0P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of thiazolamine and imidazolamine derivs. for treatment of respiratory, cardiovascular, neurol., and gastrointestinal disorders)
RN 1058720-71-0 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



IT 1058720-69-6
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of thiazolamine and imidazolamine derivs. for treatment of respiratory, cardiovascular, neurol., and gastrointestinal disorders)
RN 1058720-69-6 HCAPLUS
CN Phenol, 4-[1-[(4,5-dihydro-2-thiazolyl)amino]-2-phenylethyl]- (CA INDEX

NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 9 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2008:1072767 HCAPLUS
DOCUMENT NUMBER: 149:301349
TITLE: Synergistic pesticidal compositions comprising aminothiazoline derivatives
INVENTOR(S): Langewald, Juergen; Kordes, Markus; Culbertson, Deborah L.; Anspaugh, Douglas D.
PATENT ASSIGNEE(S): BASF SE, Germany
SOURCE: PCT Int. Appl., 125pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008104503	A1	20080904	WO 2008-EP52158	20080222

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2007-892365P P 20070301
GI



I

AB Synergistic pesticidal mixts. comprise aminothiazoline derivs. I (R1 = H, COMe, COCH2OMe, COCH2Me or COCH2CMe2; R2 = F, Cl, Br, CF3, Me or MeO; R3 = H, F, Cl, Br, CF3 or Me; R2R3 = OCF2O or OCH2O of a 5-membered fused heterocyclic ring; R4 = H, F, Cl, Br, CF3, MeO or Me; R5,R6 = H, Cl, F, Br Me, MeO or CF3) and at least one active compound selected from acetylcholine esterase inhibitors, GABA-gated chloride channel antagonists, sodium channel modulators, nicotinic acetylcholine receptor agonists/antagonists, chloride channel activators, juvenile hormone mimics, compds. affecting oxidative phosphorylation, inhibitors of chitin biosynthesis, molting disruptors, inhibitors of MET, voltage-dependent sodium channel blockers, inhibitors of lipid synthesis and other compds.. The pesticides are insecticides, acaricides and nematocides.

IT 1050434-43-9 1050434-46-2 1050434-47-3
1050434-50-8 1050434-53-1 1050434-54-2
1050434-57-5
RL: AGR (Agricultural use); BIOL (Biological study); USES (Uses)
(synergistic pesticidal composition)

RN 1050434-43-9 HCAPLUS

CN INDEX NAME NOT YET ASSIGNED

CM 1

CRN 1050433-36-7
CMF C21 H26 N2 S



CM 2

CRN 71751-41-2

CMF Unspecified
CCI MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 1050434-46-2 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

CM 1

CRN 1050433-36-7
CMF C21 H26 N2 S



CM 2

CRN 153719-23-4
CMF C8 H10 Cl N5 O3 S



RN 1050434-47-3 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

CM 1

CRN 1050433-36-7
CMF C21 H26 N2 S



CM 2

CRN 120068-37-3
CMF C12 H4 Cl2 F6 N4 O S



RN 1050434-50-8 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

CM 1

CRN 1050433-36-7
CMF C21 H26 N2 S



CM 2

CRN 123312-89-0
CMF C10 H11 N5 O

Double bond geometry as shown.



RN 1050434-53-1 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

CM 1

CRN 1050433-36-7
CMF C21 H26 N2 S



CM 2

CRN 96489-71-3
CMF C19 H25 Cl N2 O S



RN 1050434-54-2 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

CM 1

CRN 1050433-36-7

CMF C21 H26 N2 S



CM 2

CRN 67375-30-8
CMF C22 H19 Cl2 N O3

Relative stereochemistry.



RN 1050434-57-5 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

CM 1

CRN 1050433-36-7
CMF C21 H26 N2 S



CM 2

CRN 500008-45-7

CMF C18 H14 Br Cl2 N5 O2



IT 1050433-36-7D, mixts. containing 1050433-40-3D, mixts. containing 1050433-41-4D, mixts. containing 1050433-42-5D, mixts. containing 1050433-45-8D, mixts. containing 1050433-48-1D, mixts. containing 1050433-50-5D, mixts. containing 1050433-52-7D, mixts. containing 1050433-55-0D, mixts. containing 1050433-57-2D, mixts. containing 1050433-60-7D, mixts. containing 1050433-62-9D, mixts. containing 1050433-65-2D, mixts. containing 1050433-67-4D, mixts. containing 1050433-69-6D, mixts. containing 1050433-72-1D, mixts. containing 1050433-74-3D, mixts. containing 1050433-77-6D, mixts. containing 1050433-79-8D, mixts. containing 1050433-82-3D, mixts. containing 1050433-85-6D, mixts. containing 1050433-88-9D, mixts. containing 1050433-90-3D, mixts. containing 1050433-93-6D, mixts. containing 1050433-95-8D, mixts. containing 1050433-99-2D, mixts. containing 1050434-00-8D, mixts. containing 1050434-03-1D, mixts. containing 1050434-04-2D, mixts. containing 1050434-08-6D, mixts. containing 1050434-12-2D, mixts. containing 1050434-13-3D, mixts. containing 1050434-18-8D, mixts. containing 1050434-22-4D, mixts. containing 1050434-24-6D, mixts. containing 1050434-27-9D, mixts. containing 1050434-29-1D, mixts. containing 1050434-31-5D, mixts. containing 1050434-32-6D, mixts. containing 1050434-38-2D, mixts. containing
RL: AGR (Agricultural use); BIOL (Biological study); USES (Uses)
(synergistic pesticidal compns.)

RN 1050433-36-7 HCAPLUS

CN 2-Thiazolamine, N-[1-(2,3-dimethylphenyl)-2-(3,5-dimethylphenyl)ethyl]-4,5-dihydro- (CA INDEX NAME)



RN 1050433-40-3 HCAPLUS
CN 2-Thiazolamine, N-[1-(2,3-dichlorophenyl)-2-(3,5-dimethylphenyl)ethyl]-4,5-dihydro- (CA INDEX NAME)



RN 1050433-41-4 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1050433-42-5 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1050433-45-8 HCAPLUS
CN 2-Thiazolamine, N-[1-[2-chloro-5-(trifluoromethyl)phenyl]-2-(3-methylphenyl)ethyl]-4,5-dihydro- (CA INDEX NAME)



RN 1050433-48-1 HCAPLUS
CN 2-Thiazolamine, N-[1-(2,5-dichlorophenyl)-2-(3,5-dimethylphenyl)ethyl]-4,5-dihydro- (CA INDEX NAME)



RN 1050433-50-5 HCAPLUS
CN 2-Thiazolamine, N-[1-(2,5-dimethylphenyl)-2-(3-methylphenyl)ethyl]-4,5-dihydro- (CA INDEX NAME)



RN 1050433-52-7 HCAPLUS
CN 2-Thiazolamine, N-[1-(2,5-dimethylphenyl)-2-(3,5-dimethylphenyl)ethyl]-4,5-dihydro- (CA INDEX NAME)



RN 1050433-55-0 HCAPLUS
CN 2-Thiazolamine, N-[1-(2,5-difluorophenyl)-2-(3,5-dimethylphenyl)ethyl]-4,5-dihydro- (CA INDEX NAME)



RN 1050433-57-2 HCAPLUS
CN 2-Thiazolamine, N-[1-(2,5-difluorophenyl)-2-(3-methylphenyl)ethyl]-4,5-dihydro- (CA INDEX NAME)



RN 1050433-60-7 HCAPLUS
CN 2-Thiazolamine, N-[1-[2-chloro-5-(trifluoromethyl)phenyl]-2-(3,5-dimethylphenyl)ethyl]-4,5-dihydro- (CA INDEX NAME)



RN 1050433-62-9 HCAPLUS
CN 2-Thiazolamine, N-[1-(2,5-dimethoxyphenyl)-2-(3,5-dimethylphenyl)ethyl]-4,5-dihydro- (CA INDEX NAME)



RN 1050433-65-2 HCAPLUS
CN 2-Thiazolamine, N-[1-(2,5-dimethoxyphenyl)-2-(3-methylphenyl)ethyl]-4,5-dihydro- (CA INDEX NAME)



RN 1050433-67-4 HCAPLUS
CN 2-Thiazolamine, N-[1-(5-bromo-2-fluorophenyl)-2-(3,5-dimethylphenyl)ethyl]-4,5-dihydro- (CA INDEX NAME)



RN 1050433-69-6 HCAPLUS
CN 2-Thiazolamine, N-[1-(5-bromo-2-methoxyphenyl)-2-(3,5-dimethylphenyl)ethyl]-4,5-dihydro- (CA INDEX NAME)



RN 1050433-72-1 HCAPLUS
CN 2-Thiazolamine, N-[1-(2-bromo-5-fluorophenyl)-2-(3,5-dimethylphenyl)ethyl]-4,5-dihydro- (CA INDEX NAME)



RN 1050433-74-3 HCAPLUS
CN 2-Thiazolamine, N-[1-(2-bromo-5-methoxyphenyl)-2-(3-methylphenyl)ethyl]-4,5-dihydro- (CA INDEX NAME)



RN 1050433-77-6 HCAPLUS
CN 2-Thiazolamine, N-[1-(5-fluoro-2-methoxyphenyl)-2-(3-methylphenyl)ethyl]-4,5-dihydro- (CA INDEX NAME)



RN 1050433-79-8 HCAPLUS
CN 2-Thiazolamine, N-[1-[5-chloro-2-(trifluoromethyl)phenyl]-2-(3-methylphenyl)ethyl]-4,5-dihydro- (CA INDEX NAME)



RN 1050433-82-3 HCAPLUS
CN 2-Thiazolamine, N-[1-(2-fluoro-5-methylphenyl)-2-(3-methylphenyl)ethyl]-4,5-dihydro- (CA INDEX NAME)



RN 1050433-85-6 HCAPLUS
CN 2-Thiazolamine, N-[2-(3,5-dimethylphenyl)-1-(5-fluoro-2-methylphenyl)ethyl]-4,5-dihydro- (CA INDEX NAME)



RN 1050433-88-9 HCAPLUS
CN 2-Thiazolamine, N-[2-(3,5-dimethylphenyl)-1-(2-fluoro-5-methylphenyl)ethyl]-4,5-dihydro- (CA INDEX NAME)



RN 1050433-90-3 HCAPLUS
CN 2-Thiazolamine, N-[1-[5-chloro-2-(trifluoromethyl)phenyl]-2-(3,5-dimethylphenyl)ethyl]-4,5-dihydro- (CA INDEX NAME)



RN 1050433-93-6 HCAPLUS
CN 2-Thiazolamine, N-[2-(3,5-dimethylphenyl)-1-(5-fluoro-2-methoxyphenyl)ethyl]-4,5-dihydro- (CA INDEX NAME)



RN 1050433-95-8 HCAPLUS
CN 2-Thiazolamine, N-[1-(2-bromo-5-methoxyphenyl)-2-(3,5-dimethylphenyl)ethyl]-4,5-dihydro- (CA INDEX NAME)



RN 1050433-99-2 HCAPLUS
CN 2-Thiazolamine, N-[1-(5-fluoro-2-methylphenyl)-2-(3-methylphenyl)ethyl]-4,5-dihydro- (CA INDEX NAME)



RN 1050434-00-8 HCAPLUS
CN Ethanone, 1-[2-[[2-(3,5-dimethylphenyl)-1-[2-methyl-3-(trifluoromethyl)phenyl]ethyl]imino]-3-thiazolidinyl]- (CA INDEX NAME)



RN 1050434-03-1 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1050434-04-2 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1050434-08-6 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1050434-12-2 HCAPLUS
CN 1-Butanone, 1-[2-[[2-(3,5-dimethylphenyl)-1-[2-methyl-3-(trifluoromethyl)phenyl]ethyl]imino]-3-thiazolidinyl]-3,3-dimethyl- (CA INDEX NAME)



RN 1050434-13-3 HCAPLUS
CN Ethanone, 1-[2-[[2-(3,5-dimethylphenyl)-1-[2-methyl-3-(trifluoromethyl)phenyl]ethyl]imino]-3-thiazolidinyl]-2-methoxy- (CA INDEX NAME)



RN 1050434-18-8 HCAPLUS
CN 1-Propanone, 1-[2-[[2-(3,5-dimethylphenyl)-1-[2-methyl-3-(trifluoromethyl)phenyl]ethyl]imino]-3-thiazolidinyl]- (CA INDEX NAME)



RN 1050434-22-4 HCAPLUS
CN 2-Thiazolamine, N-[1-(2,3-dichlorophenyl)-2-(3,5-dichlorophenyl)ethyl]-4,5-dihydro- (CA INDEX NAME)



RN 1050434-24-6 HCAPLUS
CN 2-Thiazolamine, N-[2-(3,5-dichlorophenyl)-1-(2,3-dimethylphenyl)ethyl]-4,5-dihydro- (CA INDEX NAME)



RN 1050434-27-9 HCAPLUS
CN 2-Thiazolamine, N-[2-(3,5-dimethylphenyl)-1-[2-fluoro-3-(trifluoromethyl)phenyl]ethyl]-4,5-dihydro- (CA INDEX NAME)



RN 1050434-29-1 HCAPLUS
CN 2-Thiazolamine, N-[2-(3,5-dimethylphenyl)-1-[2-methyl-3-(trifluoromethyl)phenyl]ethyl]-4,5-dihydro- (CA INDEX NAME)



RN 1050434-31-5 HCAPLUS
CN 2-Thiazolamine, N-[1-[2-chloro-3-(trifluoromethyl)phenyl]-2-(3,5-dimethylphenyl)ethyl]-4,5-dihydro- (CA INDEX NAME)



RN 1050434-32-6 HCAPLUS
CN 2-Thiazolamine, N-[2-[3,5-bis(trifluoromethyl)phenyl]-1-(2,3-dichlorophenyl)ethyl]-4,5-dihydro- (CA INDEX NAME)



RN 1050434-38-2 HCAPLUS
CN 2-Thiazolamine, N-[2-(3-chloro-5-fluorophenyl)-1-(2,3-dichlorophenyl)ethyl]-4,5-dihydro- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:1250800 HCAPLUS
DOCUMENT NUMBER: 145:501088
TITLE: Preparation of insecticidal and acaricidal substituted benzylamino heterocyclic and heteroaryl derivatives
INVENTOR(S): Dixson, John A.; Theodoridis, George; Elshenawy, Zeinab M.; Dugan, Benjamin J.; Patel, Manorama M.;

Barron, Edward J.; Donovan, Stephen F.
PATENT ASSIGNEE(S): FMC Corporation, USA
SOURCE: PCT Int. Appl., 79pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006127426	A2	20061130	WO 2006-US19365	20060519
WO 2006127426	A3	20071101		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
AU 2006251901	A1	20061130	AU 2006-251901	20060519
EP 1885180	A2	20080213	EP 2006-784438	20060519
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
IN 2007DN08633	A	20071214	IN 2007-DN8633	20071108
MX 200714225	A	20080207	MX 2007-14225	20071113
KR 2008018891	A	20080228	KR 2007-729241	20071214

PRIORITY APPLN. INFO.: US 2005-682460P P 20050519
WO 2006-US19365 W 20060519

OTHER SOURCE(S): MARPAT 145:501088

AB The substituted benzylamino heterocyclic and heteroaryl derivs. RCR1R2NR3R4 [R = (un)substituted Ph or 1-naphthyl; R1, R2 = H, Me or Et; R3 = H, Me, Et, P(:X)R5R6, etc.; R4 = N-containing 5-membered heterocyclyl; R5,R6 = OMe or OEt] are prepd as insecticides and acaricides.

IT 858862-83-6P 858862-85-8P
RL: AGR (Agricultural use); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation as insecticide and acaricide)

RN 858862-83-6 HCAPLUS
CN 2-Oxazolamine, N-(1,2-diphenylethyl)-4,5-dihydro- (CA INDEX NAME)



RN 858862-85-8 HCAPLUS
CN 2-Thiazolamine, N-(1,2-diphenylethyl)-4,5-dihydro- (CA INDEX NAME)



L4 ANSWER 4 OF 9 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:612267 HCAPLUS
DOCUMENT NUMBER: 143:133360
TITLE: Preparation of 1-[(azolin-2-yl)amino]-1,2-diphenylethanes for combatting insects, arachnids and nematodes
INVENTOR(S): Kordes, Markus; Hofmann, Michael; Puhl, Michael; Goetz, Norbert; Rack, Michael; Baumann, Ernst; Von Deyn, Wolfgang; Schmidt, Thomas; Tedeschi, Livio; Treacy, Michael F.; Culbertson, Deborah L.; Bucci, Toni; Kuhn, David G.
PATENT ASSIGNEE(S): BASF Aktiengesellschaft, Germany
SOURCE: PCT Int. Appl., 93 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2005063724	A1	20050714	WO 2004-EP14623		20041222
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
AU 2004309067	A1	20050714	AU 2004-309067		20041222
CA 2548322	A1	20050714	CA 2004-2548322		20041222
EP 1713786	A1	20061025	EP 2004-804218		20041222
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS					
CN 1898218	A	20070117	CN 2004-80038909		20041222
BR 2004018151	A	20070417	BR 2004-18151		20041222
JP 2007519626	T	20070719	JP 2006-546063		20041222
MX 2006PA06501	A	20060823	MX 2006-PA6501		20060608
US 20070149582	A1	20070628	US 2006-583710		20060620
IN 2006CN02294	A	20070608	IN 2006-CN2294		20060623
PRIORITY APPLN. INFO.:			US 2003-531612P	P	20031223
			WO 2004-EP14623	W	20041222

OTHER SOURCE(S): CASREACT 143:133360; MARPAT 143:133360

GI



I

Q1 = 

Q2 = 

AB Title compds. [I; A = Q1, Q2; m, n = 0-5; X = S, O; R1, R2 = halo, OH, SH, NH2, SO3H, CO2H, cyano, NO2, (substituted) alkyl, alkoxy, alkylamino, alkenyl, alkenyloxy, alkenylamino, alkynyl, alkynyloxy, alkynyloxycarbonyl, alkenylcarbonyloxy, etc.; R3, R4 = H, (substituted) alkyl, haloalkyl, cycloalkyl, Ph, PhCH2; R5-R5c = H, (substituted) alkyl, haloalkyl, alkylamino, alkoxy, cycloalkyl, Ph, PhCH2; R6, R7 = H, cyano, NO2, CHO, (substituted) alkylcarbonyl, alkoxycarbonyl, alkylthiocarbonyl, etc.], were prepared Thus, 1-[2-(3-chlorophenyl)-2-phenylethyl]-(4,5-dihydrothiazol-2-yl)amine was stirred overnight with K2CO3, Et3N, and Me chloroformate in DMF to give Me [2-(3-chlorophenyl)-1-phenylethylimino]thiazolidine-3-carboxylate. The latter at 300 ppm gave >80% mortality against Aphis gossypii on cotton plants.

IT 858862-82-5P
RL: AGR (Agricultural use); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of azolinylaminodiphenylethanes as insecticides, acaricides, and nematocides)

RN 858862-82-5 HCAPLUS

CN 2-Thiazolamine, N-[1-(4-chlorophenyl)-2-phenylethyl]-4,5-dihydro- (CA INDEX NAME)



IT 858862-80-3P 858862-81-4P 858862-83-6P
858862-84-7P 858862-85-8P 858862-86-9P
858862-87-0P 858862-88-1P 858862-89-2P
858862-90-5P 858862-91-6P 858862-92-7P
858862-93-8P 858862-94-9P 858862-95-0P

858862-96-1P 858862-97-2P 858862-98-3P
858862-99-4P 858863-00-0P 858863-01-1P
858863-02-2P 858863-03-3P 858863-04-4P
858863-05-5P 858863-06-6P 858863-07-7P
858863-08-8P 858863-09-9P 858863-10-2P
858863-11-3P 858863-12-4P 858863-13-5P
858863-14-6P 858863-15-7P 858863-16-8P
858863-17-9P 858863-18-0P 858863-19-1P
858863-20-4P 858863-21-5P 858863-22-6P
858863-23-7P 858863-24-8P 858863-25-9P
858863-26-0P 858863-27-1P 858863-28-2P
858863-29-3P 858863-30-6P 858863-31-7P
858863-32-8P 858863-33-9P 858863-34-0P
858863-35-1P 858863-36-2P 858863-37-3P
858863-38-4P 858863-39-5P 858863-40-8P
858863-41-9P 858863-42-0P 858863-43-1P
858863-44-2P 858863-45-3P 858863-46-4P
858863-47-5P 858863-48-6P 858863-49-7P
858863-50-0P 858863-51-1P 858863-52-2P
858863-53-3P 858863-54-4P 858863-55-5P
858863-56-6P 858863-57-7P 858863-58-8P
858863-59-9P 858863-60-2P 858863-61-3P
858863-62-4P 858863-63-5P 858863-64-6P
858863-65-7P 858863-67-9P 858863-69-1P
858863-71-5P 858863-73-7P 858863-75-9P
858863-77-1P 858863-79-3P 858863-81-7P
858863-83-9P 858863-85-1P 858863-87-3P
858863-90-8P 858863-92-0P 858863-94-2P
858863-95-3P 858863-96-4P 858863-97-5P
858863-98-6P 858863-99-7P 858864-00-3P
858864-01-4P 858864-02-5P 858864-03-6P
858864-04-7P 858864-05-8P 858864-06-9P
858864-07-0P 858864-08-1P 858864-09-2P
858864-10-5P 858864-11-6P 858864-12-7P
858864-13-8P 858864-14-9P 858864-15-0P
858864-16-1P 858864-17-2P 858864-18-3P
858864-19-4P 858864-20-7P 858864-21-8P
858864-22-9P 858864-23-0P 858864-24-1P
858864-25-2P 858864-26-3P 858864-27-4P
858864-28-5P 858864-29-6P 858864-30-9P
858864-31-0P 858864-32-1P 858864-33-2P
858864-34-3P 858864-35-4P 858864-36-5P
858864-37-6P 858864-38-7P 858864-39-8P
858864-40-1P 858864-41-2P 858864-42-3P
858864-43-4P 858864-44-5P 858864-45-6P
858864-46-7P 858864-47-8P 858864-48-9P
858864-49-0P 858864-50-3P 858864-51-4P
858864-52-5P 858864-56-9P 859164-35-5P
RL: AGR (Agricultural use); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of azolinylaminodiphenylethanes as insecticides, acaricides, and nematocides)

RN 858862-80-3 HCAPLUS
CN 2-Oxazolamine, N-[2-(3-chlorophenyl)-1-phenylethyl]-4,5-dihydro-4-methyl- (CA INDEX NAME)



RN 858862-81-4 HCAPLUS
CN 2-Oxazolamine, N-[2-(4-fluorophenyl)-1-phenylethyl]-4,5-dihydro- (CA INDEX NAME)



RN 858862-83-6 HCAPLUS
CN 2-Oxazolamine, N-(1,2-diphenylethyl)-4,5-dihydro- (CA INDEX NAME)



RN 858862-84-7 HCAPLUS
CN 2-Thiazolamine, N-[2-(3-chlorophenyl)-1-phenylethyl]-4,5-dihydro- (CA INDEX NAME)



RN 858862-85-8 HCAPLUS
CN 2-Thiazolamine, N-(1,2-diphenylethyl)-4,5-dihydro- (CA INDEX NAME)



RN 858862-86-9 HCAPLUS
CN 2-Thiazolamine, 4,5-dihydro-N-[2-(3-methylphenyl)-1-phenylethyl]- (CA INDEX NAME)



RN 858862-87-0 HCAPLUS
CN 2-Thiazolamine, 4-butyl-N-[2-(3-chlorophenyl)-1-phenylethyl]-4,5-dihydro- (CA INDEX NAME)



RN 858862-88-1 HCAPLUS
CN 2-Thiazolamine, N-[2-(3-chlorophenyl)-1-phenylethyl]-4,5-dihydro-4-(phenylmethyl)- (CA INDEX NAME)



RN 858862-89-2 HCAPLUS
CN 2-Thiazolamine, N-[2-(3-chlorophenyl)-1-phenylethyl]-4,5-dihydro-4,5-dimethyl- (CA INDEX NAME)



RN 858862-90-5 HCAPLUS
CN 2-Thiazolamine, N-[2-(3-chlorophenyl)-1-phenylethyl]-4,5-dihydro-4-methyl-5-phenyl- (CA INDEX NAME)



RN 858862-91-6 HCAPLUS
CN 2-Thiazolamine, N-[2-(3-chlorophenyl)-1-phenylethyl]-4,5-dihydro-5-phenyl- (CA INDEX NAME)



RN 858862-92-7 HCAPLUS
CN 2-Thiazolamine, N-(1,2-diphenylethyl)-4,5-dihydro-5-phenyl- (CA INDEX NAME)



RN 858862-93-8 HCAPLUS
CN 2-Thiazolamine, N-[2-(2-fluorophenyl)-1-phenylethyl]-4,5-dihydro- (CA INDEX NAME)



RN 858862-94-9 HCAPLUS
CN 2-Thiazolamine, N-[2-(4-chlorophenyl)-1-phenylethyl]-4,5-dihydro- (CA INDEX NAME)



RN 858862-95-0 HCAPLUS
CN 2-Thiazolamine, 4,5-dihydro-5-methyl-N-[2-(3-methylphenyl)-1-phenylethyl]- (CA INDEX NAME)



RN 858862-96-1 HCAPLUS
CN 2-Thiazolamine, 4,5-dihydro-N-[2-(3-methylphenyl)-1-phenylethyl]-5-phenyl- (CA INDEX NAME)



RN 858862-97-2 HCAPLUS
CN 2-Thiazolamine, N-[2-(3-fluorophenyl)-1-phenylethyl]-4,5-dihydro- (CA INDEX NAME)



RN 858862-98-3 HCAPLUS
CN 2-Thiazolamine, N-[2-(3-chloro-4-fluorophenyl)-1-phenylethyl]-4,5-dihydro- (CA INDEX NAME)



RN 858862-99-4 HCAPLUS
CN 2-Thiazolamine, N-[2-(3,4-difluorophenyl)-1-phenylethyl]-4,5-dihydro- (CA INDEX NAME)



RN 858863-00-0 HCAPLUS
CN 2-Thiazolamine, N-[2-(4-bromophenyl)-1-phenylethyl]-4,5-dihydro- (CA INDEX NAME)



RN 858863-01-1 HCAPLUS
CN 2-Oxazolamine, N-[1-(3,5-dimethoxyphenyl)-2-phenylethyl]-4,5-dihydro- (CA INDEX NAME)



RN 858863-02-2 HCAPLUS
CN 2-Oxazolamine, N-[2-(3-chlorophenyl)-1-phenylethyl]-4,5-dihydro- (CA INDEX NAME)



RN 858863-03-3 HCAPLUS
CN 2-Oxazolamine, 4,5-dihydro-N-[2-(4-methylphenyl)-1-phenylethyl]- (CA INDEX NAME)



RN 858863-04-4 HCAPLUS
CN 2-Oxazolamine, N-[2-(2-bromophenyl)-1-phenylethyl]-4,5-dihydro- (CA INDEX NAME)



RN 858863-05-5 HCAPLUS
CN 2-Oxazolamine, N-[2-(2,4-dichlorophenyl)-1-phenylethyl]-4,5-dihydro- (CA INDEX NAME)



RN 858863-06-6 HCAPLUS
CN 2-Oxazolamine, N-[1-(3,4-dichlorophenyl)-2-phenylethyl]-4,5-dihydro- (CA INDEX NAME)



RN 858863-07-7 HCAPLUS
CN 2-Oxazolamine, N-(1,2-diphenylethyl)-4,5-dihydro-4,4-dimethyl- (CA INDEX NAME)



RN 858863-08-8 HCAPLUS
CN 2-Oxazolamine, N-(1,2-diphenylethyl)-4,5-dihydro-5-methyl- (CA INDEX NAME)



RN 858863-09-9 HCAPLUS
CN 2-Oxazolamine, N-(1,2-diphenylethyl)-4-ethyl-4,5-dihydro- (CA INDEX NAME)



RN 858863-10-2 HCAPLUS
CN 2-Oxazolamine, N-(1,2-diphenylethyl)-4,5-dihydro-4,5-dimethyl- (CA INDEX NAME)



RN 858863-11-3 HCAPLUS
CN 2-Oxazolamine, N-(1,2-diphenylethyl)-4,5-dihydro-4-methyl- (CA INDEX NAME)



RN 858863-12-4 HCAPLUS
CN 2-Oxazolamine, N-[2-(2-fluorophenyl)-1-phenylethyl]-4,5-dihydro- (CA INDEX NAME)



RN 858863-13-5 HCAPLUS
CN 2-Oxazolamine, N-[2-(3,5-difluorophenyl)-1-phenylethyl]-4,5-dihydro- (CA INDEX NAME)



RN 858863-14-6 HCAPLUS
CN 2-Oxazolamine, N-[2-(3-fluorophenyl)-1-phenylethyl]-4,5-dihydro- (CA INDEX NAME)



RN 858863-15-7 HCAPLUS
CN 2-Oxazolamine, N-[2-(3-chlorophenyl)-1-phenylethyl]-4,5-dihydro-4,4-dimethyl- (CA INDEX NAME)



RN 858863-16-8 HCAPLUS
CN 2-Oxazolamine, N-[2-(3-chlorophenyl)-1-phenylethyl]-4,5-dihydro-5-methyl- (CA INDEX NAME)



RN 858863-17-9 HCAPLUS
CN 2-Oxazolamine, N-[2-(3-chlorophenyl)-1-phenylethyl]-4-ethyl-4,5-dihydro- (CA INDEX NAME)



RN 858863-18-0 HCAPLUS
CN 2-Oxazolamine, N-[2-(3-chlorophenyl)-1-phenylethyl]-4,5-dihydro-4,5-dimethyl- (CA INDEX NAME)



RN 858863-19-1 HCAPLUS
CN 2-Oxazolamine, N-[2-(3,4-dichlorophenyl)-1-phenylethyl]-4,5-dihydro- (CA INDEX NAME)



RN 858863-20-4 HCAPLUS
CN 2-Oxazolamine, N-[2-(2-chlorophenyl)-1-phenylethyl]-4,5-dihydro- (CA INDEX NAME)



RN 858863-21-5 HCAPLUS
CN 2-Oxazolamine, N-[2-(3-bromophenyl)-1-phenylethyl]-4,5-dihydro- (CA INDEX NAME)



RN 858863-22-6 HCAPLUS
CN 2-Oxazolamine, N-[2-(2,6-dichlorophenyl)-1-phenylethyl]-4,5-dihydro- (CA INDEX NAME)



RN 858863-23-7 HCAPLUS
CN 3-Thiazolidinecarboxylic acid, 2-[[2-(3-chlorophenyl)-1-phenylethyl]imino]-, methyl ester (CA INDEX NAME)



RN 858863-24-8 HCAPLUS
CN 3-Thiazolidinecarbonitrile, 2-[[2-(3-chlorophenyl)-1-phenylethyl]imino]- (CA INDEX NAME)



RN 858863-25-9 HCAPLUS
CN Benzeneethanamine, N-(3-ethyl-2-thiazolidinylidene)-α-phenyl- (CA INDEX NAME)



RN 858863-26-0 HCAPLUS
CN Benzeneethanamine, 3-chloro-N-(3-ethyl-2-thiazolidinylidene)-α-phenyl- (CA INDEX NAME)



RN 858863-27-1 HCAPLUS
CN Benzeneethanamine, 3-fluoro-N-(3-methyl-2-oxazolidinylidene)-α-phenyl- (CA INDEX NAME)



RN 858863-28-2 HCAPLUS
CN 2-Thiazolamine, 4,5-dihydro-N-[2-(4-methylphenyl)-1-phenylethyl]- (CA INDEX NAME)



RN 858863-29-3 HCAPLUS
CN 2-Thiazolamine, N-[2-(3-bromophenyl)-1-phenylethyl]-4,5-dihydro- (CA INDEX NAME)



RN 858863-30-6 HCAPLUS
CN 2-Thiazolamine, N-[2-(2-chlorophenyl)-1-(4-fluorophenyl)ethyl]-4,5-dihydro- (CA INDEX NAME)



RN 858863-31-7 HCAPLUS
CN 2-Thiazolamine, 4,5-dihydro-N-[2-(2-methylphenyl)-1-phenylethyl]- (CA INDEX NAME)



RN 858863-32-8 HCAPLUS
CN 2-Thiazolamine, N-[1,2-bis(4-methoxyphenyl)ethyl]-4,5-dihydro- (CA INDEX NAME)



RN 858863-33-9 HCAPLUS
CN 2-Thiazolamine, 4,5-dihydro-N-[1-(4-methylphenyl)-2-phenylethyl]- (CA INDEX NAME)



RN 858863-34-0 HCAPLUS
CN 2-Thiazolamine, 4,5-dihydro-N-[1-(3-methylphenyl)-2-phenylethyl]- (CA INDEX NAME)



RN 858863-35-1 HCAPLUS
CN 2-Thiazolamine, 4,5-dihydro-N-[1-phenyl-2-[3-(trifluoromethyl)phenyl]ethyl]- (CA INDEX NAME)



RN 858863-36-2 HCAPLUS
CN 2-Thiazolamine, N-[2-(2-chloro-4-fluorophenyl)-1-phenylethyl]-4,5-dihydro- (CA INDEX NAME)



RN 858863-37-3 HCAPLUS
CN 2-Thiazolamine, N-[2-(3,5-dichlorophenyl)-1-phenylethyl]-4,5-dihydro- (CA INDEX NAME)



RN 858863-38-4 HCAPLUS
CN 2-Thiazolamine, 4,5-dihydro-N-[2-(2,3,4,5,6-pentafluorophenyl)-1-phenylethyl]- (CA INDEX NAME)



RN 858863-39-5 HCAPLUS
CN 2-Thiazolamine, N-[2-(3'-fluoro[1,1'-biphenyl]-3-yl)-1-phenylethyl]-4,5-dihydro- (CA INDEX NAME)



RN 858863-40-8 HCAPLUS
CN 2-Thiazolamine, 4,5-dihydro-N-[2-(4'-methoxy[1,1'-biphenyl]-3-yl)-1-phenylethyl]- (CA INDEX NAME)



RN 858863-41-9 HCAPLUS
CN 2-Thiazolamine, N-[1-(2,6-dichlorophenyl)-2-phenylethyl]-4,5-dihydro- (CA INDEX NAME)



RN 858863-42-0 HCAPLUS
CN 2-Thiazolamine, N-[1-(2,3-dichlorophenyl)-2-(3-methylphenyl)ethyl]-4,5-dihydro- (CA INDEX NAME)



RN 858863-43-1 HCAPLUS
CN 2-Thiazolamine, N-[1-(2,6-dichlorophenyl)-2-(3-methylphenyl)ethyl]-4,5-dihydro- (CA INDEX NAME)



RN 858863-44-2 HCAPLUS
CN 2-Thiazolamine, N-[1-(4-ethylphenyl)-2-phenylethyl]-4,5-dihydro- (CA INDEX NAME)



RN 858863-45-3 HCAPLUS
CN 2-Thiazolamine, 4,5-dihydro-N-[1-[4-(methylthio)phenyl]-2-phenylethyl]- (CA INDEX NAME)



RN 858863-46-4 HCAPLUS
CN 2-Thiazolamine, N-[1-(2,3-dichlorophenyl)-2-phenylethyl]-4,5-dihydro- (CA INDEX NAME)



RN 858863-47-5 HCAPLUS
CN 2-Thiazolamine, N-[1,2-bis(3-chlorophenyl)ethyl]-4,5-dihydro- (CA INDEX NAME)



RN 858863-48-6 HCAPLUS
CN 2-Thiazolamine, 4,5-dihydro-N-[1-(3-methoxyphenyl)-2-phenylethyl]- (CA INDEX NAME)



RN 858863-49-7 HCAPLUS
CN 2-Thiazolamine, N-[1-(2,4-dimethylphenyl)-2-phenylethyl]-4,5-dihydro- (CA INDEX NAME)



RN 858863-50-0 HCAPLUS
CN 2-Thiazolamine, N-[1-[4-(1,1-dimethylethoxy)phenyl]-2-phenylethyl]-4,5-dihydro- (CA INDEX NAME)



RN 858863-51-1 HCAPLUS
CN 2-Thiazolamine, N-[1-(3-ethoxyphenyl)-2-phenylethyl]-4,5-dihydro- (CA INDEX NAME)



RN 858863-52-2 HCAPLUS
CN 2-Thiazolamine, N-[1-(2-ethoxyphenyl)-2-phenylethyl]-4,5-dihydro- (CA INDEX NAME)





RN 858863-53-3 HCAPLUS
CN 2-Thiazolamine, N-[1-(2-ethylphenyl)-2-phenylethyl]-4,5-dihydro- (CA INDEX NAME)



RN 858863-54-4 HCAPLUS
CN 2-Thiazolamine, N-[2-(2-chlorophenyl)-1-phenylethyl]-4,5-dihydro- (CA INDEX NAME)



RN 858863-55-5 HCAPLUS
CN 2-Thiazolamine, N-[1-(4-ethylphenyl)-2-(3-methylphenyl)ethyl]-4,5-dihydro- (CA INDEX NAME)



RN 858863-56-6 HCAPLUS
CN 2-Thiazolamine, 4,5-dihydro-N-[2-(3-methylphenyl)-1-[4-(methylthio)phenyl]ethyl]- (CA INDEX NAME)



RN 858863-57-7 HCAPLUS
CN 2-Thiazolamine, N-[1-(2-chlorophenyl)-2-phenylethyl]-4,5-dihydro- (CA INDEX NAME)



RN 858863-58-8 HCAPLUS
CN 2-Thiazolamine, N-[1-(3-chlorophenyl)-2-phenylethyl]-4,5-dihydro- (CA INDEX NAME)



RN 858863-59-9 HCAPLUS
CN 2-Thiazolamine, N-[1-(2-chlorophenyl)-2-(3-methylphenyl)ethyl]-4,5-dihydro-

(CA INDEX NAME)



RN 858863-60-2 HCAPLUS
CN 2-Thiazolamine, 4,5-dihydro-N-[1-(2-methoxyphenyl)-2-phenylethyl]- (CA INDEX NAME)





RN 858863-61-3 HCAPLUS
CN 2-Thiazolamine, N-[1-(4-chlorophenyl)-2-(3-methylphenyl)ethyl]-4,5-dihydro- (CA INDEX NAME)



RN 858863-62-4 HCAPLUS
CN 2-Thiazolamine, N-[1-(2-fluorophenyl)-2-phenylethyl]-4,5-dihydro- (CA INDEX NAME)





RN 858863-63-5 HCAPLUS
CN 2-Thiazolamine, N-[1-(4-fluorophenyl)-2-phenylethyl]-4,5-dihydro- (CA INDEX NAME)



RN 858863-64-6 HCAPLUS
CN 2-Thiazolamine, 4,5-dihydro-N-[1-(2-methylphenyl)-2-(3-methylphenyl)ethyl]- (CA INDEX NAME)



RN 858863-65-7 HCAPLUS
CN 2-Thiazolamine, N-[1,2-bis(3-methylphenyl)ethyl]-4,5-dihydro- (CA INDEX NAME)



RN 858863-67-9 HCAPLUS

CN 2-Thiazolamine, N-[1-(3-fluorophenyl)-2-phenylethyl]-4,5-dihydro- (CA INDEX NAME)



RN 858863-69-1 HCAPLUS
CN 2-Thiazolamine, N-[1-(2-bromophenyl)-2-phenylethyl]-4,5-dihydro- (CA INDEX NAME)



RN 858863-71-5 HCAPLUS
CN 2-Thiazolamine, N-[1-(3-bromophenyl)-2-phenylethyl]-4,5-dihydro- (CA INDEX NAME)



RN 858863-73-7 HCAPLUS
CN 2-Oxazolamine, 4,5-dihydro-N-[1-phenyl-2-[3-(trifluoromethyl)phenyl]ethyl]- (CA INDEX NAME)



RN 858863-75-9 HCAPLUS
CN 2-Thiazolamine, N-[1-[4-(1,1-dimethylethyl)-2-methylphenyl]-2-phenylethyl]-4,5-dihydro-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl

RN 858863-77-1 HCAPLUS
CN 2-Thiazolamine, N-[1-(2,3-dichloro-4-methoxyphenyl)-2-phenylethyl]-4,5-dihydro- (CA INDEX NAME)





RN 858863-79-3 HCAPLUS
CN 2-Thiazolamine, 4,5-dihydro-N-[1-(4-methoxyphenyl)-2-phenylethyl]- (CA INDEX NAME)



RN 858863-81-7 HCAPLUS
CN 2-Thiazolamine, N-[1-(3-chlorophenyl)-2-(3-methylphenyl)ethyl]-4,5-dihydro- (CA INDEX NAME)



RN 858863-83-9 HCAPLUS
CN 2-Thiazolamine, 4,5-dihydro-N-[1-(2-methoxyphenyl)-2-(3-methylphenyl)ethyl]- (CA INDEX NAME)



RN 858863-85-1 HCAPLUS
CN 2-Thiazolamine, 4,5-dihydro-N-[1-(4-methoxyphenyl)-2-(3-methylphenyl)ethyl]- (CA INDEX NAME)



RN 858863-87-3 HCAPLUS
CN 2-Thiazolamine, 4,5-dihydro-N-[1-(3-methoxyphenyl)-2-(3-methylphenyl)ethyl]- (CA INDEX NAME)



RN 858863-90-8 HCAPLUS
CN 2-Thiazolamine, N-[2-(3,5-dimethoxyphenyl)-1-phenylethyl]-4,5-dihydro- (CA INDEX NAME)



RN 858863-92-0 HCAPLUS
CN 2-Thiazolamine, N-[1-(4-bromophenyl)-2-phenylethyl]-4,5-dihydro- (CA INDEX NAME)



RN 858863-94-2 HCAPLUS
CN 2-Thiazolamine, 4,5-dihydro-N-[2-phenyl-1-[3-(phenylmethoxy)phenyl]ethyl]- (CA INDEX NAME)



RN 858863-95-3 HCAPLUS
CN 2-Thiazolamine, N-[1-(2-fluorophenyl)-2-(3-methylphenyl)ethyl]-4,5-dihydro- (CA INDEX NAME)



RN 858863-96-4 HCAPLUS
CN 2-Thiazolamine, N-[1-(3-fluorophenyl)-2-(3-methylphenyl)ethyl]-4,5-dihydro- (CA INDEX NAME)



RN 858863-97-5 HCAPLUS
CN 2-Thiazolamine, N-[1-[2-(2-buten-1-yloxy)phenyl]-2-phenylethyl]-4,5-dihydro- (CA INDEX NAME)



RN 858863-98-6 HCAPLUS
CN 2-Thiazolamine, N-[1-(2,3-dimethoxyphenyl)-2-phenylethyl]-4,5-dihydro- (CA INDEX NAME)



RN 858863-99-7 HCAPLUS
CN 2-Thiazolamine, N-[1-[2-[(4-chlorophenyl)thio]phenyl]-2-phenylethyl]-4,5-dihydro- (CA INDEX NAME)



RN 858864-00-3 HCAPLUS
CN 2-Thiazolamine, 4,5-dihydro-N-[1-[3-methoxy-2-(phenylmethoxy)phenyl]-2-

phenylethyl]- (CA INDEX NAME)



RN 858864-01-4 HCAPLUS
CN 2-Thiazolamine, 4,5-dihydro-N-[1-(2-methyl[1,1'-biphenyl]-3-yl)-2-phenylethyl]- (CA INDEX NAME)



RN 858864-02-5 HCAPLUS
CN 2-Thiazolamine, 4,5-dihydro-N-[2-phenyl-1-[2-(trifluoromethyl)[1,1'-biphenyl]-3-yl]ethyl]- (CA INDEX NAME)



RN 858864-03-6 HCAPLUS
CN 2-Thiazolamine, N-[1-(2,3-difluorophenyl)-2-phenylethyl]-4,5-dihydro- (CA INDEX NAME)



RN 858864-04-7 HCAPLUS
CN 2-Thiazolamine, N-[1-(3-fluoro-2-methylphenyl)-2-phenylethyl]-4,5-dihydro- (CA INDEX NAME)



RN 858864-05-8 HCAPLUS
CN 2-Thiazolamine, N-[1-[2-fluoro-3-(trifluoromethyl)phenyl]-2-phenylethyl]-4,5-dihydro- (CA INDEX NAME)



RN 858864-06-9 HCAPLUS
CN 2-Thiazolamine, N-[1-(4-fluorophenyl)-2-(3-methylphenyl)ethyl]-4,5-dihydro- (CA INDEX NAME)



RN 858864-07-0 HCAPLUS
CN 2-Thiazolamine, 4,5-dihydro-N-[2-(3-methylphenyl)-1-(4-methylphenyl)ethyl]- (CA INDEX NAME)



RN 858864-08-1 HCAPLUS

CN 2-Thiazolamine, N-[1-(2,3-dimethoxyphenyl)-2-(3-methylphenyl)ethyl]-4,5-dihydro- (CA INDEX NAME)



RN 858864-09-2 HCAPLUS
CN 2-Thiazolamine, N-[1-[2-(2-buten-1-yloxy)phenyl]-2-(3-methylphenyl)ethyl]-4,5-dihydro- (CA INDEX NAME)



RN 858864-10-5 HCAPLUS
CN 2-Thiazolamine, N-[1-(2,3-dimethylphenyl)-2-phenylethyl]-4,5-dihydro- (CA INDEX NAME)



RN 858864-11-6 HCAPLUS
CN 2-Thiazolamine, N-[1-(2,3-difluorophenyl)-2-(3-methylphenyl)ethyl]-4,5-dihydro- (CA INDEX NAME)



RN 858864-12-7 HCAPLUS
CN 2-Thiazolamine, N-[1-(2,3-dimethylphenyl)-2-(3-methylphenyl)ethyl]-4,5-dihydro- (CA INDEX NAME)



RN 858864-13-8 HCAPLUS
CN 2-Thiazolamine, N-[1-[2-chloro-3-(trifluoromethyl)phenyl]-2-phenylethyl]-4,5-dihydro- (CA INDEX NAME)



RN 858864-14-9 HCAPLUS
CN 2-Oxazolamine, 4,5-dihydro-N-[2-(3-methylphenyl)-1-phenylethyl]- (CA INDEX NAME)



RN 858864-15-0 HCAPLUS
CN 2-Thiazolamine, 4,5-dihydro-N-[1-[2-methyl-3-(trifluoromethyl)phenyl]-2-

phenylethyl]- (CA INDEX NAME)



RN 858864-16-1 HCAPLUS
CN 2-Thiazolamine, N-[1-[3-[4-(1,1-dimethylethyl)phenoxy]phenyl]-2-(3-methylphenyl)ethyl]-4,5-dihydro- (CA INDEX NAME)



RN 858864-17-2 HCAPLUS
CN 2-Thiazolamine, 4,5-dihydro-N-[2-(3-methylphenyl)-1-[3-(trifluoromethoxy)phenyl]ethyl]- (CA INDEX NAME)



RN 858864-18-3 HCAPLUS
CN 2-Thiazolamine, N-[1-(3-chloro-2-fluorophenyl)-2-phenylethyl]-4,5-dihydro- (CA INDEX NAME)



RN 858864-19-4 HCAPLUS
CN 2-Thiazolamine, N-[1-(3-fluoro-2-methylphenyl)-2-(3-methylphenyl)ethyl]-4,5-dihydro- (CA INDEX NAME)



RN 858864-20-7 HCAPLUS
CN 2-Thiazolamine, N-[1-[2-fluoro-3-(trifluoromethyl)phenyl]-2-(3-methylphenyl)ethyl]-4,5-dihydro- (CA INDEX NAME)



RN 858864-21-8 HCAPLUS
CN 2-Thiazolamine, N-[1-[2-chloro-3-(trifluoromethyl)phenyl]-2-(3-methylphenyl)ethyl]-4,5-dihydro- (CA INDEX NAME)



RN 858864-22-9 HCAPLUS
CN 2-Thiazolamine, N-[1-(3-chloro-2-fluorophenyl)-2-(3-methylphenyl)ethyl]-4,5-dihydro- (CA INDEX NAME)



RN 858864-23-0 HCAPLUS
CN 2-Thiazolamine, 4,5-dihydro-N-[2-(3-methylphenyl)-1-[2-methyl-3-(trifluoromethyl)phenyl]ethyl]- (CA INDEX NAME)



RN 858864-24-1 HCAPLUS
CN 2-Oxazolamine, N-[1-(2,3-dichlorophenyl)-2-(4-methylphenyl)ethyl]-4,5-dihydro- (CA INDEX NAME)



RN 858864-25-2 HCAPLUS
CN 2-Oxazolamine, N-[1-(4-chloro-2-fluorophenyl)-2-(3-methylphenyl)ethyl]-4,5-dihydro- (CA INDEX NAME)



RN 858864-26-3 HCAPLUS
CN 2-Oxazolamine, N-[1-(2-chloro-4-fluorophenyl)-2-(3-methylphenyl)ethyl]-4,5-dihydro- (CA INDEX NAME)



RN 858864-27-4 HCAPLUS
CN 2-Thiazolamine, 4,5-dihydro-N-[1-phenyl-2-[4-(phenylmethyl)phenyl]ethyl]- (CA INDEX NAME)



RN 858864-28-5 HCAPLUS
CN 2-Thiazolamine, N-[1-(2,3-dichlorophenyl)-2-[4-(phenylmethyl)phenyl]ethyl]-4,5-dihydro- (CA INDEX NAME)



RN 858864-29-6 HCAPLUS
CN 2-Thiazolamine, 4,5-dihydro-N-[2-(3-methylphenyl)-1-(2,4,5-trifluorophenyl)ethyl]- (CA INDEX NAME)



RN 858864-30-9 HCAPLUS
CN 2-Thiazolamine, N-[1-(2,3-dichlorophenyl)-2-(2,4-dimethylphenyl)ethyl]-4,5-dihydro- (CA INDEX NAME)



RN 858864-31-0 HCAPLUS
CN 2-Thiazolamine, N-[2-(3,4-dimethylphenyl)-1-phenylethyl]-4,5-dihydro- (CA INDEX NAME)



RN 858864-32-1 HCAPLUS
CN 2-Oxazolamine, N-[1-(3,5-dibromophenyl)-2-(3-methylphenyl)ethyl]-4,5-dihydro- (CA INDEX NAME)



RN 858864-33-2 HCAPLUS
CN 2-Oxazolamine, N-[1-(2,5-dichlorophenyl)-2-(3-methylphenyl)ethyl]-4,5-dihydro- (CA INDEX NAME)



RN 858864-34-3 HCAPLUS
CN 2-Thiazolamine, N-[1-(2,5-dichlorophenyl)-2-(3-methylphenyl)ethyl]-4,5-dihydro- (CA INDEX NAME)



RN 858864-35-4 HCAPLUS
CN 2-Thiazolamine, N-[1-(3,5-dibromophenyl)-2-(3-methylphenyl)ethyl]-4,5-dihydro- (CA INDEX NAME)



RN 858864-36-5 HCAPLUS
CN 2-Thiazolamine, N-[1-(2,3-dichloro-4-methylphenyl)-2-(3-methylphenyl)ethyl]-4,5-dihydro- (CA INDEX NAME)



RN 858864-37-6 HCAPLUS
CN 2-Thiazolamine, 4,5-dihydro-N-[2-(3-methylphenyl)-1-(2,3,6-trifluorophenyl)ethyl]- (CA INDEX NAME)



RN 858864-38-7 HCAPLUS
CN 2-Thiazolamine, 4,5-dihydro-N-[2-(3-methylphenyl)-1-(2,3,5-trifluorophenyl)ethyl]- (CA INDEX NAME)



RN 858864-39-8 HCAPLUS
CN 2-Thiazolamine, N-[1-(3-chloro-2,6-difluorophenyl)-2-(3-methylphenyl)ethyl]-4,5-dihydro- (CA INDEX NAME)



RN 858864-40-1 HCAPLUS
CN 2-Thiazolamine, N-[1-(2-bromophenyl)-2-(3-methylphenyl)ethyl]-4,5-dihydro- (CA INDEX NAME)



RN 858864-41-2 HCAPLUS
CN 2-Thiazolamine, N-[1-(3-bromophenyl)-2-(3-methylphenyl)ethyl]-4,5-dihydro- (CA INDEX NAME)



RN 858864-42-3 HCAPLUS
CN 2-Thiazolamine, N-[1-(4-bromophenyl)-2-(3-methylphenyl)ethyl]-4,5-dihydro- (CA INDEX NAME)



RN 858864-43-4 HCAPLUS
CN 2-Thiazolamine, N-[1-(2-chloro-6-fluorophenyl)-2-(3-methylphenyl)ethyl]-4,5-dihydro- (CA INDEX NAME)



RN 858864-44-5 HCAPLUS
CN 2-Thiazolamine, N-[1-(2,4-dichlorophenyl)-2-(3-methylphenyl)ethyl]-4,5-dihydro- (CA INDEX NAME)



RN 858864-45-6 HCAPLUS
CN 2-Thiazolamine, N-[1-(3,4-dichlorophenyl)-2-(3-methylphenyl)ethyl]-4,5-dihydro- (CA INDEX NAME)



RN 858864-46-7 HCAPLUS
CN 2-Thiazolamine, N-[1-(3,5-difluorophenyl)-2-(3-methylphenyl)ethyl]-4,5-dihydro- (CA INDEX NAME)



RN 858864-47-8 HCAPLUS
CN 2-Oxazolamine, N-[1-(2,3-dichlorophenyl)-2-(3-methylphenyl)ethyl]-4,5-dihydro- (CA INDEX NAME)



RN 858864-48-9 HCAPLUS
CN 2-Oxazolamine, N-[1-(3,4-dichlorophenyl)-2-(3-methylphenyl)ethyl]-4,5-dihydro- (CA INDEX NAME)



RN 858864-49-0 HCAPLUS
CN 2-Oxazolamine, N-[1-(2-chloro-6-fluorophenyl)-2-(3-methylphenyl)ethyl]-4,5-dihydro- (CA INDEX NAME)



RN 858864-50-3 HCAPLUS
CN 2-Oxazolamine, N-[1-(3,5-difluorophenyl)-2-(3-methylphenyl)ethyl]-4,5-dihydro- (CA INDEX NAME)



RN 858864-51-4 HCAPLUS
CN 2-Thiazolamine, N-[1-(2,3-dichlorophenyl)-2-(4-methylphenyl)ethyl]-4,5-dihydro- (CA INDEX NAME)



RN 858864-52-5 HCAPLUS
CN 2-Thiazolamine, N-[1-(5-bromo-2-fluorophenyl)-2-(3-methylphenyl)ethyl]-4,5-dihydro- (CA INDEX NAME)



RN 858864-56-9 HCAPLUS
CN 3-Oxazolidinecarboxylic acid, 2-[[2-(3-chlorophenyl)-1-phenylethyl]imino]-, methyl ester (CA INDEX NAME)



RN 859164-35-5 HCAPLUS
CN 2-Thiazolamine, 4,5-dihydro-N-[1-[2-(naphthalenylmethoxy)phenyl]-2-phenylethyl]- (9CI) (CA INDEX NAME)





REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 9 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:408246 HCAPLUS
DOCUMENT NUMBER: 140:407274
TITLE: Transition metal catalysts for (co)polymerization of olefinic monomers
PATENT ASSIGNEE(S): BASF A.-G., Germany

SOURCE: Ger. Offen., 25 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 10251513	A1	20040519	DE 2002-10251513	20021104
WO 2004041796	A1	20040521	WO 2003-EP12200	20031103
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003287981	A1	20040607	AU 2003-287981	20031103
EP 1558593	A1	20050803	EP 2003-779830	20031103
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006516954	T	20060713	JP 2004-548848	20031103
US 20060128559	A1	20060615	US 2005-533945	20050504
US 7268095	B2	20070911		

PRIORITY APPLN. INFO.: DE 2002-10251513 A 20021104
WO 2003-EP12200 W 20031103

OTHER SOURCE(S): MARPAT 140:407274

GI



I



II

AB Highly active catalysts with good stability for polymerization of olefins are based on transition metal complexes of multidentate ligands I or II (E1, E2', E3' = O, S, Se, Te, NR, CR2, or PR; E2, E3 = CR, N, or P; E4 = N or P; E5 = OH, SH, NHR, OR', SR', or NRR'; E6 = NH, PH, NR', or PR'; R5, R6 = H, linear, branched, or cyclic alkyl, or aryl; R1, R2, R3, R4 = H, linear, branched, or cyclic alkyl, aryl, halo, or NO2; R = H or linear, branched, or cyclic alkyl; R' = linear, branched, or cyclic alkyl; ≥1 of E5

and E6 = H). A typical ligand was manufactured by refluxing EtOH containing 2-aminothiazole 2.71, 3,5-di-tert-butyl-2-hydroxybenzaldehyde 6.35, and piperidine 0.08 g, and reduction of the imino group in the resulting 4,6-di-tert-butyl-2-(thiazol-2-yliminomethyl)phenol with NaBH4 in MeOH to an amino group.

IT 690678-25-2P
RL: IMF (Industrial manufacture); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)
(ligand; highly active catalysts with good stability based on transition metal complexes for multidentate heterocyclic ligands for (co)polymerization of olefinic monomers)

RN 690678-25-2 HCAPLUS
CN Phenol, 2,4-bis(1,1-dimethylethyl)-6-[2-phenyl-1-(2-thiazolylamino)ethyl]- (CA INDEX NAME)



L4 ANSWER 6 OF 9 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:1001986 HCAPLUS
DOCUMENT NUMBER: 140:314408
TITLE: 1,2-Diaryl-1-ethanone and pyrazolo [4,3-c] quinoline-4-one as novel selective cyclooxygenase-2 inhibitors
AUTHOR(S): Baruah, Bipul; Dasu, Kavitha; Vaitilingam, Balasubramanian; Vanguri, Akhila; Casturi, Seshagiri Rao; Yeleswarapu, Koteswar Rao
CORPORATE SOURCE: Discovery Research, Inflammation Research Group, Dr. Reddy's Laboratories Limited, Miyapur, Hyderabad, 500050, India
SOURCE: Bioorganic & Medicinal Chemistry Letters (2004), 14(2), 445-448
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 140:314408

AB Novel 1,2-diaryl-1-ethanone 1 and pyrazolo [4,3-c] quinoline-4-one 2, with pharmacophores different from the known COX inhibitors were identified as selective COX-2 inhibitors. The communication briefly describes structure-activity relationship (SAR) of both the series.

IT 678143-21-0P 678143-22-1P 678143-23-2P
678143-24-3P 678143-28-7P
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and structure-activity relationship studies of 1,2-diaryl-1-ethanone and pyrazolo [4,3-c] quinoline-4-one as novel selective cyclooxygenase-2 inhibitors)

RN 678143-21-0 HCAPLUS
CN Ethanone, 1-[4-(methylsulfinyl)phenyl]-2-phenyl-2-(2-thiazolylamino)- (CA INDEX NAME)



RN 678143-22-1 HCAPLUS
CN Ethanone, 1-[4-(methylsulfonyl)phenyl]-2-phenyl-2-(2-thiazolylamino)- (CA INDEX NAME)



RN 678143-23-2 HCAPLUS
CN Ethanone, 1-(4-fluorophenyl)-2-[4-(methylsulfinyl)phenyl]-2-(2-thiazolylamino)- (CA INDEX NAME)



RN 678143-24-3 HCAPLUS
CN Ethanone, 1-(4-fluorophenyl)-2-[4-(methylsulfonyl)phenyl]-2-(2-thiazolylamino)- (CA INDEX NAME)



RN 678143-28-7 HCAPLUS
CN Benzenesulfonamide, 4-[2-(4-fluorophenyl)-2-oxo-1-(2-thiazolylamino)ethyl]-
(CA INDEX NAME)



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 9 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1981:443104 HCAPLUS
DOCUMENT NUMBER: 95:43104
ORIGINAL REFERENCE NO.: 95:7381a
TITLE: Bicyclic thiadiaza compounds and their use as medicaments
INVENTOR(S): Goeschke, Richard; Ferrini, Pier Giorgio
PATENT ASSIGNEE(S): Ciba-Geigy A.-G., Switz.
SOURCE: Brit. UK Pat. Appl., 11 pp.
CODEN: BAXXDU
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
GB 2039882	A	19800820	GB 1979-427		19790105
PRIORITY APPLN. INFO.:			GB 1979-427	A	19790105
OTHER SOURCE(S):	MARPAT 95:43104				

GI



I

AB The preparation of the title compds. I (R, R1 = optionally substituted Ph, pyridyl, thienyl; X = C2-4 alkylene; n = 0, 1, 2) is described. Thus, 5,6-bis(p-methoxyphenyl)imidazolo[2,1-b]dihydrothiazole (II) was prepared from 4,5-bis(p-methoxyphenyl)-2-mercaptoimidazole by treatment with 1.5% NaOH-Br(CH2)2Br-NaCO3-Me2CHOH (6 h, reflux) followed by treatment with 20% KOH. I have antiinflammatory, antirheumatic, analgesic, antithrombotic, and prostaglandin synthetase-inhibiting activity. They are useful in the treatment of rheumatoid arthritis. Compns. containing II are described.

IT 70827-22-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and cyclocondensation reaction of)

RN 70827-22-4 HCAPLUS

CN Benzeneethanol, 4-methoxy-α-(4-methoxyphenyl)-β-(2-thiazolylamino)- (CA INDEX NAME)



L4 ANSWER 8 OF 9 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1979:457003 HCAPLUS
DOCUMENT NUMBER: 91:57003
ORIGINAL REFERENCE NO.: 91:9239a,9242a
TITLE: Bicyclic thiadiaza compounds
PATENT ASSIGNEE(S): Ciba-Geigy A.-G., Switz.
SOURCE: Jpn. Kokai Tokkyo Koho, 12 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 54016470	A	19790207	JP 1978-81533	19780706

EP 353		A2	19790124	EP 1978-100272	19780629
R: BE, CH, DE, FR, GB, NL, SE					
EP 19688		A1	19810210	EP 1980-101323	19780629
R: BE, CH, DE, FR, GB, NL, SE					
FI 7802132		A	19790108	FI 1978-2132	19780703
AU 7837788		A	19800110	AU 1978-37788	19780705
DK 7803055		A	19790108	DK 1978-3055	19780706
NO 7802357		A	19790109	NO 1978-2357	19780706
ZA 7803898		A	19790725	ZA 1978-3898	19780706
DD 138212		A5	19791017	DD 1978-206565	19780706
AT 7804917		A	19800315	AT 1978-4917	19780706
AT 359078		B	19801027		
DD 145538		A5	19801217	DD 1978-214990	19780706
SU 873886		A3	19811015	SU 1978-2632647	19780706
HU 29077		A2	19840130	HU 1981-3495	19780706
PL 116596		B1	19810630	PL 1978-208253	19780707
SU 893134		A3	19811223	SU 1979-2763599	19790518
AT 7906667		A	19800615	AT 1979-6667	19791012
AT 360526		B	19810112		
AT 7906668		A	19800615	AT 1979-6668	19791012
AT 360527		B	19810112		
AT 7906669		A	19800615	AT 1979-6669	19791012
AT 360528		B	19810112		
SU 850007		A3	19810723	SU 1979-2831085	19791023
SU 873887		A3	19811015	SU 1979-2855458	19791220
ES 487583		A5	19810116	ES 1980-487583	19800110
EP 20858		A1	19810107	EP 1980-101322	19800313
R: BE, CH, DE, FR, GB, NL, SE					

PRIORITY APPLN. INFO.:

LU 1977-77703	A	19770707
AT 1978-4917	A	19780706
US 1979-2565	A	19790111
US 1979-47084	A	19790611
JP 1979-103495	A	19790814

OTHER SOURCE(S): MARPAT 91:57003

GI



I II



III

AB I and II (R, R1 = Ph, pyridyl, thienyl; X = alkylene; n = 0, 1, 2; m = 1, 2) were prepared, e.g. by cyclization of III. I and II were antiinflammatory agents (10 mg/kg). Thus, heating p-MeOC6H4COCHBrC6H4OMe-p with 2-aminothiazoline in EtOH 4 h at 60°, refluxing 2 h and stirring 12 h at room temperature gave II (R = R1 = p-MeOC6H4, m = 1).

IT 70827-22-4

RL: RCT (Reactant); RACT (Reactant or reagent)
(cyclization of, imidazothiazole derivative from)
RN 70827-22-4 HCAPLUS
CN Benzeneethanol, 4-methoxy-α-(4-methoxyphenyl)-β-(2-thiazolylamino)- (CA INDEX NAME)



IT 70827-24-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with hydrogen bromide)
RN 70827-24-6 HCAPLUS
CN Ethanone, 1,2-bis(4-methoxyphenyl)-2-(2-thiazolylamino)- (CA INDEX NAME)



L4 ANSWER 9 OF 9 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1954:826 HCAPLUS
DOCUMENT NUMBER: 48:826
ORIGINAL REFERENCE NO.: 48:141h-i,142a-d
TITLE: Tertiary amines derived from N-(2-pyridyl, 2-thiazolyl, and 2-lepidyl)-1,2-diphenylethylamine
AUTHOR(S): Kaye, Irving Allan; Parris, Chester L.
CORPORATE SOURCE: Brooklyn Coll., Brooklyn, NY
SOURCE: Journal of the American Chemical Society (1952), 74, 1566-8
CODEN: JACSAT; ISSN: 0002-7863
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
AB cf. C.A. 47, 8746c. Some secondary amines could be alkylated in the presence of LiNH2 with alkyl halides and styrene oxide to yield products desired for testing as potential antimitotic agents, reaction between CH2PhCHPhCl (I) and either 2-aminopyridine (II) or N,N-dimethyl-N'-(2-pyridyl)ethylenediamine (III) under the same conditions

yielded only trans-stilbene. Preliminary pharmacol. tests of the ability of the compds. prepared to retard the growth of sarcoma 180, or as antihistamine agents are reported. All m.ps. are corrected 2-Chlorolepidine (30.2 g.) and 67.1 g. CH2PhCH(Ph)NH2 (IV) let react until the temperature fell to 100°, 300 cc. C6H6 added, the mixture refluxed 12 hrs., IV.HCl filtered off (m. 256-8°), and the filtrate evaporated yielded 29.6 g. 2-(1,2-diphenylethyl)aminolepidine, m. 135-6°. IV (59.2 g.) yielded 68.6 g. 1,2-diphenylethyl isothiocyanate (V), b0.07 120-1°. V (62.2 g.) in 150 cc. each Me2CO and concentrated NH4OH yielded 63.7 g. N-(1,2-diphenylethyl)thiourea (VI), m. 171-1.5°. VI (28.2 g.), 15.0 g. ClCH2CH(OMe)2, and 100 cc. water heated 2.5 hrs. on the steam bath, dilute NaOH added, the gum extracted with Et2O and the Et2O evaporated yielded 2-(1,2-diphenylethyl)aminothiazole. 2-(1,2-Diphenylethylamino)pyridine (13.9 g.), 7.2 g. styrene oxide, 1.5 g. LiNH2, and 100 cc. C6H6 refluxed 24 hrs., the mixture shaken with 500 cc. water, and the C6H6 exts. evaporated, yielded 18.1 g. N-(1,2-diphenylethyl)-N-(2-pyridyl)-1-phenyl-2-aminoethanol, b0.03 200-2°. PhCH2CHPhOH (464.1 g.) in 950 cc. (CH2Cl)2 treated dropwise during 1 hr. with 350 g. SOCl2 (temperature held below 10°), the mixture let stand 18 hrs., and distilled in vacuo yielded 426.4 g. I, b5 146-9°. III (23.0 g.), 32.5 g. I, 3.9 g. LiNH2, and 150 cc. C6H6 yielded 20.2 g. trans-stilbene, m. 124-5°. The results were similar with II instead of III. For secondary and tertiary amines, PhCH2CH(Ph)NRR', R, R', b.p./mm., m.p., and yield are: 2-pyridyl (VII), H, 157-9°/0.08, 65-6°, 73 (picrate, m. 185-6.5); 2-thiazolyl, H, 200-2°/0.60, 103.5-4.5°, 84; VII, CH2CH2NMe2, 161-3°/0.05, 168.5-9.5° (oxalate), 97; VII, CH2CH2NEt2, 174-7°/0.03, 129-9.5° (oxalate), 97; VII, (CH2)3NEt2, 179-83°/0.07, -, 97: VII 2-(1-pyrrolidylethyl), 181-3/0.05, 183-4 (oxalate, decomposition), 96; VII, 2-morpholinoethyl, 205-7°/0.11, 96.5-7.5° (oxalate 176.5-77°), 98; VII, CH2CH2N(CH2Ph)2, -, 114-15°, 94; VII, CH2CH2SMe, 184-5°/0.09, 74-5°, 95; VII, CHCH(OH)Ph, 200-2°/0.03, -, 92; 2-thiazolyl, CH2CH2NMe2, 173-6°/0.02, 142-3° (picrate), 82; 2-lepidyl, CH2CH2NMe2, 215-17°/0.04, 171-2° (picrate), 93.

IT 859474-57-0P, Thiazole, 2-(1,2-diphenylethylamino)-
859477-34-2P, Thiazole, 2-[(2-dimethylaminoethyl)(1,2-diphenylethyl)amino]- 859477-35-3P, Thiazole, 2-[(2-dimethylaminoethyl)(1,2-diphenylethyl)amino]-, picrate
RL: PREP (Preparation)
(preparation of)

RN 859474-57-0 HCAPLUS
CN 2-Thiazolamine, N-(1,2-diphenylethyl)- (CA INDEX NAME)



RN 859477-34-2 HCAPLUS
CN 1,2-Ethanediamine, N1-(1,2-diphenylethyl)-N2,N2-dimethyl-N1-2-thiazolyl- (CA INDEX NAME)



RN 859477-35-3 HCAPLUS
CN Thiazole, 2-[(2-dimethylaminoethyl)(1,2-diphenylethyl)amino]-, picrate (5CI) (CA INDEX NAME)

CM 1

CRN 859477-34-2
CMF C21 H25 N3 S



CM 2

CRN 88-89-1
CMF C6 H3 N3 O7



=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	81.54	260.11
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-9.60	-9.60

STN INTERNATIONAL LOGOFF AT 13:06:49 ON 16 OCT 2008